SG11202112171XA - Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof - Google Patents
Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereofInfo
- Publication number
- SG11202112171XA SG11202112171XA SG11202112171XA SG11202112171XA SG11202112171XA SG 11202112171X A SG11202112171X A SG 11202112171XA SG 11202112171X A SG11202112171X A SG 11202112171XA SG 11202112171X A SG11202112171X A SG 11202112171XA SG 11202112171X A SG11202112171X A SG 11202112171XA
- Authority
- SG
- Singapore
- Prior art keywords
- heteroarylaminopyrimidine
- amide
- methods
- autophagy inhibitors
- autophagy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962846264P | 2019-05-10 | 2019-05-10 | |
| US201962846260P | 2019-05-10 | 2019-05-10 | |
| US201962911736P | 2019-10-07 | 2019-10-07 | |
| US201962911733P | 2019-10-07 | 2019-10-07 | |
| PCT/US2020/032090 WO2020231808A1 (en) | 2019-05-10 | 2020-05-08 | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112171XA true SG11202112171XA (en) | 2021-12-30 |
Family
ID=70847594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112171XA SG11202112171XA (en) | 2019-05-10 | 2020-05-08 | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11518758B2 (lt) |
| EP (2) | EP3966206B1 (lt) |
| JP (1) | JP2022531932A (lt) |
| KR (1) | KR20220019696A (lt) |
| CN (1) | CN114072397A (lt) |
| AU (2) | AU2020274011B2 (lt) |
| BR (1) | BR112021022576A2 (lt) |
| CA (1) | CA3139120A1 (lt) |
| CL (1) | CL2021002953A1 (lt) |
| CO (1) | CO2021016765A2 (lt) |
| DK (1) | DK3966206T3 (lt) |
| ES (1) | ES2962852T3 (lt) |
| FI (1) | FI3966206T3 (lt) |
| HR (1) | HRP20231310T1 (lt) |
| HU (1) | HUE064465T2 (lt) |
| IL (1) | IL287795A (lt) |
| LT (1) | LT3966206T (lt) |
| MX (1) | MX2021013662A (lt) |
| PE (1) | PE20220592A1 (lt) |
| PL (1) | PL3966206T3 (lt) |
| PT (1) | PT3966206T (lt) |
| RS (1) | RS64755B1 (lt) |
| SG (1) | SG11202112171XA (lt) |
| SI (1) | SI3966206T1 (lt) |
| TW (1) | TW202108574A (lt) |
| WO (1) | WO2020231808A1 (lt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111818915B (zh) | 2018-01-31 | 2024-05-24 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| KR20210119411A (ko) | 2018-12-28 | 2021-10-05 | 데시페라 파마슈티칼스, 엘엘씨. | 암 치료에 사용하기 위한 csf1r 억제제 |
| JP2022517222A (ja) | 2019-01-10 | 2022-03-07 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| CA3139120A1 (en) | 2019-05-10 | 2020-11-19 | Deciphera Pharmaceuticals, Llc | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| PT3966207T (pt) | 2019-05-10 | 2023-12-20 | Deciphera Pharmaceuticals Llc | Inibidores de autofagia de fenilaminopirimidina amida e métodos de utilização dos mesmos |
| CN114258318A (zh) | 2019-06-17 | 2022-03-29 | 德西费拉制药有限责任公司 | 氨基嘧啶酰胺自噬抑制剂及其使用方法 |
| EP4013412A1 (en) | 2019-08-12 | 2022-06-22 | Deciphera Pharmaceuticals, LLC | Ripretinib for treating gastrointestinal stromal tumors |
| WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| EP4021444A4 (en) | 2019-08-29 | 2023-01-04 | Mirati Therapeutics, Inc. | G12D KRAS INHIBITORS |
| CN114761012A (zh) | 2019-09-24 | 2022-07-15 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| IL294048A (en) | 2019-12-20 | 2022-08-01 | Mirati Therapeutics Inc | sos1 inhibitors |
| KR20220123058A (ko) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물 |
| IL293866A (en) | 2019-12-30 | 2022-08-01 | Deciphera Pharmaceuticals Llc | Compositions of amorphous kinase inhibitors and methods of using them |
| MX2023005747A (es) | 2020-11-18 | 2023-07-28 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos. |
| CN113527294A (zh) * | 2021-08-25 | 2021-10-22 | 都创(上海)医药开发有限公司 | Mrtx849化合物的晶型及其制备方法和用途 |
| CN115894404A (zh) * | 2021-09-22 | 2023-04-04 | 杭州天玑济世生物科技有限公司 | 一类具有萘胺结构的小分子化合物及其应用 |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262088B1 (en) | 1998-11-19 | 2001-07-17 | Berlex Laboratories, Inc. | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
| GB9910807D0 (en) | 1999-05-10 | 1999-07-07 | Prometic Biosciences Limited | Novel detoxification agents and their use |
| US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
| AU783981C (en) | 2000-05-08 | 2007-05-03 | Janssen Pharmaceutica N.V. | HIV replication inhibitors |
| HUP0402352A2 (hu) | 2001-06-19 | 2005-02-28 | Bristol-Myers Squibb Co. | Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények |
| PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| JP4510442B2 (ja) | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | ＴＮＦ−α発現のＮ−ヘテロ環インヒビター |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| WO2003032994A2 (de) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
| CA2463989C (en) | 2001-10-17 | 2012-01-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof |
| JP4072615B2 (ja) | 2002-03-05 | 2008-04-09 | 独立行政法人産業技術総合研究所 | 配位子を有する複素環化合物及びその製造方法、及びこの複素環化合物を用いる金属元素の固定化膜 |
| WO2004048343A1 (en) | 2002-11-28 | 2004-06-10 | Schering Aktiengesellschaft | Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| CL2004000303A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
| CA2531232A1 (en) | 2003-07-16 | 2005-02-10 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| EP1656372B1 (en) | 2003-07-30 | 2013-04-10 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
| SI1663242T1 (sl) | 2003-08-07 | 2011-09-30 | Rigel Pharmaceuticals Inc | 2,4-pirimidindiaminske spojine in uporabe kot antiproliferativna sredstva |
| EP1763514A2 (en) | 2004-05-18 | 2007-03-21 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| PE20060530A1 (es) | 2004-06-04 | 2006-06-28 | Arena Pharm Inc | Aril y heteroaril derivados sustituidos como moduladores del metabolismo de la glucosa |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| CA2592118C (en) | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
| EP1838308B1 (en) | 2005-01-07 | 2010-06-30 | F. Hoffmann-Roche AG | [4-(heteroaryl)piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| US20070032493A1 (en) | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
| CN101484433A (zh) | 2006-02-15 | 2009-07-15 | 艾博特公司 | 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用 |
| CA2650611A1 (en) | 2006-05-15 | 2007-11-29 | Irm Llc | Compositions and methods for fgf receptor kinases inhibitors |
| CN101506175A (zh) | 2006-06-15 | 2009-08-12 | 贝林格尔·英格海姆国际有限公司 | 作为蛋白激酶C-α抑制剂的2-苯氨基-4-（杂环基）氨基-嘧啶 |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| CA2673965A1 (en) | 2006-12-28 | 2008-07-10 | Taisho Pharmaceutical Co., Ltd. | Pyrazolopyrimidine compound |
| CN101878031A (zh) | 2007-04-20 | 2010-11-03 | 迪赛孚尔制药有限公司 | 用于治疗骨髓增生性疾病和其他增生性疾病的激酶抑制剂 |
| CN101910151A (zh) | 2007-10-22 | 2010-12-08 | 先灵公司 | 双环杂环衍生物及其作为gpr119活性调节剂的用途 |
| WO2009122180A1 (en) | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
| US20110098221A1 (en) | 2008-06-26 | 2011-04-28 | Hong Lin | INHIBITORS OF Akt ACTIVITY |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| MX357627B (es) | 2008-06-27 | 2018-07-17 | Avila Therapeutics Inc | Compuestos de heteroarilo y usos de los mismos. |
| JP5444365B2 (ja) | 2008-10-29 | 2014-03-19 | デシフェラ ファーマシューティカルズ，エルエルシー | 抗癌活性および抗増殖活性を示すシクロプロパンアミドおよび類似物質 |
| WO2010111406A2 (en) | 2009-03-24 | 2010-09-30 | Myriad Pharmaceuticals, Inc. | Compounds and therapeutic uses thereof |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| WO2011075515A1 (en) | 2009-12-17 | 2011-06-23 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
| RU2012132473A (ru) | 2009-12-30 | 2014-02-10 | Селджин Авиломикс,Инк | Лиганд-направленная ковалентная модификация белка |
| KR20130109943A (ko) | 2010-04-29 | 2013-10-08 | 데시페라 파마슈티칼스, 엘엘씨. | 항암 및 항증식 활성을 나타내는 시클로프로필 디카르복사미드 및 유사체 |
| EP2563773A1 (en) | 2010-04-29 | 2013-03-06 | Deciphera Pharmaceuticals, LLC | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites |
| JPWO2012033195A1 (ja) | 2010-09-10 | 2014-01-20 | 京都薬品工業株式会社 | 複素環化合物 |
| EP2675793B1 (en) | 2011-02-17 | 2018-08-08 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| CA2843195A1 (en) * | 2011-07-28 | 2013-01-31 | Cellzome Limited | Heterocyclyl pyrimidine analogues as jak inhibitors |
| CN104302292A (zh) | 2011-11-22 | 2015-01-21 | 德西费拉制药有限责任公司 | 表现出抗癌和抗增殖活性的吡啶酮酰胺以及类似物 |
| WO2013079495A1 (en) | 2011-11-29 | 2013-06-06 | F. Hoffmann-La Roche Ag | 2-(phenyl or pyrid-3-yl) aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease |
| RU2634716C2 (ru) | 2011-11-29 | 2017-11-03 | Дженентек, Инк. | Производные аминопиридина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2) |
| CA2856002C (en) | 2011-11-30 | 2020-10-13 | Bryan K. Chan | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
| WO2013134298A1 (en) | 2012-03-07 | 2013-09-12 | Deciphera Pharmaceuticals, Llc | Raf inhibitor compounds |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| GB201204384D0 (en) | 2012-03-13 | 2012-04-25 | Univ Dundee | Anti-flammatory agents |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| EP2888256A4 (en) | 2012-08-24 | 2016-02-17 | Univ Texas | HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES |
| WO2014078378A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9309224B2 (en) | 2013-03-15 | 2016-04-12 | Deciphera Pharmaceuticals, Llc. | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
| DK2968286T3 (en) | 2013-03-15 | 2018-01-02 | Deciphera Pharmaceuticals Llc | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS THAT HAVE ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES |
| US9012635B2 (en) | 2013-03-15 | 2015-04-21 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
| US9193719B2 (en) | 2013-03-15 | 2015-11-24 | Deciphera Pharmaceuticals, Llc | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
| US9133183B2 (en) | 2013-03-15 | 2015-09-15 | Deciphera Pharmaceuticals, Llc | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities |
| SG11201508532VA (en) | 2013-03-15 | 2015-11-27 | Deciphera Pharmaceuticals Llc | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
| CN103242341B (zh) | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用 |
| WO2015006492A1 (en) | 2013-07-09 | 2015-01-15 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
| CN104262328B (zh) | 2013-09-18 | 2016-09-07 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
| US9840517B2 (en) | 2013-09-18 | 2017-12-12 | Beijing Hanmi Pharmaceutical Co., Ltd. | Compound inhibiting activities of BTK and/or JAK3 kinases |
| RU2715708C2 (ru) | 2013-10-18 | 2020-03-03 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Ингибиторы fgfr4 |
| PL3060550T3 (pl) | 2013-10-21 | 2019-10-31 | Merck Patent Gmbh | Związki heteroarylowe jako inhibitory btk i ich zastosowanie |
| US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
| US20150284341A1 (en) | 2014-04-07 | 2015-10-08 | Catylix, Inc. | Fluoroalkyl-substituted derivatives of pyridine, pyrimidine, and pyrazine |
| WO2016033100A1 (en) | 2014-08-25 | 2016-03-03 | Salk Institute For Biological Studies | Novel ulk1 inhibitors and methods using same |
| WO2016135163A1 (en) | 2015-02-25 | 2016-09-01 | F. Hoffmann-La Roche Ag | Alkynyl alcohols and methods of use |
| EP3328496A4 (en) | 2015-08-02 | 2018-12-19 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibitors of ack1/tnk2 tyrosine kinase |
| US10738016B2 (en) | 2015-10-13 | 2020-08-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | BRD4-kinase inhibitors as cancer therapeutics |
| US11028080B2 (en) * | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
| CA3054809A1 (en) | 2017-02-28 | 2018-09-07 | The General Hospital Corporation | Uses of pyrimidopyrimidinones as sik inhibitors |
| AU2017417160B2 (en) | 2017-05-30 | 2024-05-02 | Deciphera Pharmaceuticals, Llc | Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha |
| CN109535132B (zh) * | 2017-09-21 | 2021-07-20 | 北京赛特明强医药科技有限公司 | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 |
| KR20200115606A (ko) | 2018-01-31 | 2020-10-07 | 데시페라 파마슈티칼스, 엘엘씨. | 비만 세포증의 치료를 위한 병용 요법 |
| EP3774783A1 (en) | 2018-04-10 | 2021-02-17 | Neuropore Therapies, Inc. | Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways |
| KR20210119411A (ko) | 2018-12-28 | 2021-10-05 | 데시페라 파마슈티칼스, 엘엘씨. | 암 치료에 사용하기 위한 csf1r 억제제 |
| CA3139120A1 (en) | 2019-05-10 | 2020-11-19 | Deciphera Pharmaceuticals, Llc | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| PT3966207T (pt) | 2019-05-10 | 2023-12-20 | Deciphera Pharmaceuticals Llc | Inibidores de autofagia de fenilaminopirimidina amida e métodos de utilização dos mesmos |
| CN114258318A (zh) | 2019-06-17 | 2022-03-29 | 德西费拉制药有限责任公司 | 氨基嘧啶酰胺自噬抑制剂及其使用方法 |
-
2020
- 2020-05-08 CA CA3139120A patent/CA3139120A1/en active Pending
- 2020-05-08 PT PT207283656T patent/PT3966206T/pt unknown
- 2020-05-08 CN CN202080049743.1A patent/CN114072397A/zh active Pending
- 2020-05-08 MX MX2021013662A patent/MX2021013662A/es unknown
- 2020-05-08 WO PCT/US2020/032090 patent/WO2020231808A1/en active Application Filing
- 2020-05-08 BR BR112021022576A patent/BR112021022576A2/pt unknown
- 2020-05-08 DK DK20728365.6T patent/DK3966206T3/da active
- 2020-05-08 EP EP20728365.6A patent/EP3966206B1/en active Active
- 2020-05-08 FI FIEP20728365.6T patent/FI3966206T3/fi active
- 2020-05-08 US US16/870,418 patent/US11518758B2/en active Active
- 2020-05-08 SG SG11202112171XA patent/SG11202112171XA/en unknown
- 2020-05-08 HU HUE20728365A patent/HUE064465T2/hu unknown
- 2020-05-08 SI SI202030293T patent/SI3966206T1/sl unknown
- 2020-05-08 JP JP2021566466A patent/JP2022531932A/ja active Pending
- 2020-05-08 EP EP23190061.4A patent/EP4295846A3/en active Pending
- 2020-05-08 LT LTEPPCT/US2020/032090T patent/LT3966206T/lt unknown
- 2020-05-08 PE PE2021001871A patent/PE20220592A1/es unknown
- 2020-05-08 KR KR1020217040561A patent/KR20220019696A/ko unknown
- 2020-05-08 AU AU2020274011A patent/AU2020274011B2/en active Active
- 2020-05-08 HR HRP20231310TT patent/HRP20231310T1/hr unknown
- 2020-05-08 ES ES20728365T patent/ES2962852T3/es active Active
- 2020-05-08 RS RS20230959A patent/RS64755B1/sr unknown
- 2020-05-08 PL PL20728365.6T patent/PL3966206T3/pl unknown
- 2020-05-08 TW TW109115472A patent/TW202108574A/zh unknown
-
2021
- 2021-11-02 IL IL287795A patent/IL287795A/en unknown
- 2021-11-09 CL CL2021002953A patent/CL2021002953A1/es unknown
- 2021-12-10 CO CONC2021/0016765A patent/CO2021016765A2/es unknown
-
2022
- 2022-06-03 US US17/832,224 patent/US20230047915A1/en active Pending
-
2024
- 2024-05-14 AU AU2024203193A patent/AU2024203193A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220019696A (ko) | 2022-02-17 |
| FI3966206T3 (fi) | 2023-10-20 |
| US20230047915A1 (en) | 2023-02-16 |
| HUE064465T2 (hu) | 2024-04-28 |
| LT3966206T (lt) | 2023-11-10 |
| CO2021016765A2 (es) | 2022-04-08 |
| PT3966206T (pt) | 2023-11-10 |
| US11518758B2 (en) | 2022-12-06 |
| IL287795A (en) | 2022-01-01 |
| WO2020231808A1 (en) | 2020-11-19 |
| EP4295846A3 (en) | 2024-02-28 |
| CA3139120A1 (en) | 2020-11-19 |
| AU2020274011A1 (en) | 2021-11-25 |
| ES2962852T3 (es) | 2024-03-21 |
| HRP20231310T1 (hr) | 2024-02-02 |
| AU2020274011B2 (en) | 2024-02-15 |
| PL3966206T3 (pl) | 2024-01-29 |
| CL2021002953A1 (es) | 2022-07-15 |
| PE20220592A1 (es) | 2022-04-22 |
| EP3966206A1 (en) | 2022-03-16 |
| MX2021013662A (es) | 2022-03-11 |
| BR112021022576A2 (pt) | 2022-01-25 |
| US20200354346A1 (en) | 2020-11-12 |
| SI3966206T1 (sl) | 2023-12-29 |
| CN114072397A (zh) | 2022-02-18 |
| EP4295846A2 (en) | 2023-12-27 |
| AU2024203193A1 (en) | 2024-06-06 |
| DK3966206T3 (da) | 2023-11-13 |
| JP2022531932A (ja) | 2022-07-12 |
| EP3966206B1 (en) | 2023-08-09 |
| TW202108574A (zh) | 2021-03-01 |
| RS64755B1 (sr) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287787A (en) | Phenylaminopyrimidine amide as autophagy inhibitors and methods of using them | |
| IL287795A (en) | Heteroarylaminopyrimidine amide as autophagy inhibitors and methods of using them | |
| IL279475A (en) | Actonucleotidase inhibitors and methods of using them | |
| IL287751A (en) | kcnt1 inhibitors and methods of use | |
| IL287768A (en) | kcnt1 inhibitors and methods of use | |
| IL276711A (en) | Arginase inhibitors and methods of using them | |
| IL288996A (en) | Aminopyrimidine amide autophagy inhibitors and methods of using them | |
| IL287973A (en) | acss2 inhibitors and methods of their use | |
| EP3846808A4 (en) | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | |
| IL280924A (en) | Arginase inhibitors and methods of using them | |
| EP3959197A4 (en) | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | |
| IL264854A (en) | Spt5 inhibitors and methods of use thereof | |
| IL285108A (en) | Arginase inhibitors and methods of using them | |
| EP4077332A4 (en) | LIN28 INHIBITORS AND THEIR METHODS OF USE |